BiotechTube

PF-06423264

Phase 1Terminated
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Normal Healthy

Conditions

Normal Healthy

Trial Timeline

May 23, 2016 → May 23, 2017

NCT ID
NCT02778477

About PF-06423264

PF-06423264 is a phase 1 stage product being developed by Pfizer for Normal Healthy. The current trial status is terminated. This product is registered under clinical trial identifier NCT02778477. Target conditions include Normal Healthy.

What happened to similar drugs?

4 of 6 similar drugs in Normal Healthy were approved

Approved (4) Terminated (2) Active (2)
✅DonepezilEisaiApproved
✅Eybelis ophthalmic solution 0.002%Santen PharmaceuticalApproved
✅cyclosporine micro-emulsionNovartisApproved
✅Aspirin 100 mg + PlaceboBayerApproved
🔄Gadopentetate dimeglumine (Magnevist)BayerPhase 3
🔄lixivaptan + placeboBiogenPhase 3

Hype Score Breakdown

Clinical
6
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02778477Phase 1Terminated

Competing Products

20 competing products in Normal Healthy

See all competitors
ProductCompanyStageHype Score
RoxadustatAstellas PharmaPhase 1
29
DonepezilEisaiApproved
43
eribulin mesylateEisaiPhase 2
35
Lurasidone HClSumitomo PharmaPhase 1
29
Eybelis ophthalmic solution 0.002%Santen PharmaceuticalApproved
39
TriptorelinMerckPre-clinical
26
Temozolomide + VorinostatMerckPhase 2
35
LDE225NovartisPhase 1
29
LDK378NovartisPhase 1
29
cyclosporine micro-emulsionNovartisApproved
35
LDK378NovartisPhase 1
29
LEE011NovartisPhase 1
29
LEE011NovartisPhase 1
29
mycophenolate mofetilRochePhase 1
29
filgrastimAmgenPre-clinical
26
PF-05221304PfizerPhase 1
29
BMS-933043 + Placebo matching with BMS-933043 + Antacid Buffer Predose SolutionBristol Myers SquibbPhase 1
29
tolebrutinibSanofiPhase 1
29
Venglustat (GZ402671)SanofiPhase 1
29
RilzabrutinibSanofiPhase 1
29